@grahamabra.bsky.social
Nephrologist @StanfordNeph, Chair @HDAE_Official, Director Social Media @HemodialysisInt, Defender of the 4 nephrons.
Reposted
I realize folks have probably heard this elsewhere, but it looks like the shutdown will likely end very soon, if not tonight then tomorrow. The good health policy news is that the telehealth flexibilities will be extended until January 30 and made retroactive back to October 1. (1)
November 12, 2025 at 2:24 PM
I realize folks have probably heard this elsewhere, but it looks like the shutdown will likely end very soon, if not tonight then tomorrow. The good health policy news is that the telehealth flexibilities will be extended until January 30 and made retroactive back to October 1. (1)
Community house HD continues to be a great example of patient centered care and creative thinking
Dialysis model saves lives and millions
https://www.newsbeep.com/241229/
A world-first South Auckland dialysis model is being praised for saving lives, restoring dignity, and easing pressure on…
https://www.newsbeep.com/241229/
A world-first South Auckland dialysis model is being praised for saving lives, restoring dignity, and easing pressure on…
Dialysis model saves lives and millions - News Beep
A world-first South Auckland dialysis model is being praised for saving lives, restoring dignity, and easing pressure on Middlemore Hospital, but its future
www.newsbeep.com
November 10, 2025 at 2:35 PM
Community house HD continues to be a great example of patient centered care and creative thinking
Reposted
In the PISCES trial involving participants receiving hemodialysis, fish oil (n−3 fatty acids) was compared with corn-oil placebo. The rate of serious cardiovascular events was lower with daily fish-oil supplementation. Full trial results: nej.md/49zWuqo
@asnkidney.bsky.social | #KidneyWk
@asnkidney.bsky.social | #KidneyWk
November 7, 2025 at 4:36 PM
In the PISCES trial involving participants receiving hemodialysis, fish oil (n−3 fatty acids) was compared with corn-oil placebo. The rate of serious cardiovascular events was lower with daily fish-oil supplementation. Full trial results: nej.md/49zWuqo
@asnkidney.bsky.social | #KidneyWk
@asnkidney.bsky.social | #KidneyWk
Reposted
a conservative dialysis strategy in possibly recovering AKI helps people recover faster!
jamanetwork.com/journals/jam...
in @jama.com from #KidneyWk
Like STARRT-AKi et al, at the other end? Small trial - needs replication or this is common sense?
jamanetwork.com/journals/jam...
in @jama.com from #KidneyWk
Like STARRT-AKi et al, at the other end? Small trial - needs replication or this is common sense?
A Conservative Dialysis Strategy and Kidney Function Recovery in Dialysis-Requiring Acute Kidney Injury
This trial examines whether a conservative dialysis strategy can improve recovery of kidney function for patients with acute kidney injury who require dialysis.
jamanetwork.com
November 7, 2025 at 6:50 PM
a conservative dialysis strategy in possibly recovering AKI helps people recover faster!
jamanetwork.com/journals/jam...
in @jama.com from #KidneyWk
Like STARRT-AKi et al, at the other end? Small trial - needs replication or this is common sense?
jamanetwork.com/journals/jam...
in @jama.com from #KidneyWk
Like STARRT-AKi et al, at the other end? Small trial - needs replication or this is common sense?
Reposted
large cohort study of
CDK 4/6
BRAF
EGFR
VEGF
and other cancer treatments
#OncoNephrology #NephSky #KidneyWk
jamanetwork.com/journals/jam... from Shuchi Anand et al from @stanfordmedicine.bsky.social
CDK 4/6
BRAF
EGFR
VEGF
and other cancer treatments
#OncoNephrology #NephSky #KidneyWk
jamanetwork.com/journals/jam... from Shuchi Anand et al from @stanfordmedicine.bsky.social
November 6, 2025 at 10:30 PM
large cohort study of
CDK 4/6
BRAF
EGFR
VEGF
and other cancer treatments
#OncoNephrology #NephSky #KidneyWk
jamanetwork.com/journals/jam... from Shuchi Anand et al from @stanfordmedicine.bsky.social
CDK 4/6
BRAF
EGFR
VEGF
and other cancer treatments
#OncoNephrology #NephSky #KidneyWk
jamanetwork.com/journals/jam... from Shuchi Anand et al from @stanfordmedicine.bsky.social
Reposted
We are 2 for 2 with positive trials so far. LIBERATE-D shows benefit with a conservative vs conventional dialysis strategy in AKI-D. The difference in mortality is concerning though? Simultaneous pub 👇🏾 #kidneywk
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
November 7, 2025 at 5:10 PM
We are 2 for 2 with positive trials so far. LIBERATE-D shows benefit with a conservative vs conventional dialysis strategy in AKI-D. The difference in mortality is concerning though? Simultaneous pub 👇🏾 #kidneywk
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Reposted
Highlights from my talk yesterday on Alport syndrome spectrum of disorders. (since no one posted it, I'll have to do it myself)
Variants in type IV collagen cause a wide spectrum of disease. #KidneyWk 🧵
Variants in type IV collagen cause a wide spectrum of disease. #KidneyWk 🧵
November 6, 2025 at 6:39 PM
Highlights from my talk yesterday on Alport syndrome spectrum of disorders. (since no one posted it, I'll have to do it myself)
Variants in type IV collagen cause a wide spectrum of disease. #KidneyWk 🧵
Variants in type IV collagen cause a wide spectrum of disease. #KidneyWk 🧵
Reposted
ORIGIN phase 3 trial: In an interim analysis of a clinical trial, atacicept, a fusion protein that binds and inhibits two cytokines thought to be central to the pathophysiology of IgA nephropathy, significantly reduced proteinuria. nej.md/3JEq8QL
@asnkidney.bsky.social | #KidneyWk
@asnkidney.bsky.social | #KidneyWk
November 6, 2025 at 2:55 PM
ORIGIN phase 3 trial: In an interim analysis of a clinical trial, atacicept, a fusion protein that binds and inhibits two cytokines thought to be central to the pathophysiology of IgA nephropathy, significantly reduced proteinuria. nej.md/3JEq8QL
@asnkidney.bsky.social | #KidneyWk
@asnkidney.bsky.social | #KidneyWk
Reposted
The first-ever Home Dialysis Early Program Course is happening today at #KidneyWk2025! 🌟
Thanks to ISPD collaboration with ASN, over 100 attendees can explore the latest trends in home dialysis with great speakers from around the world. Exciting times for kidney care! 🩺#PeritonealDialysis
Thanks to ISPD collaboration with ASN, over 100 attendees can explore the latest trends in home dialysis with great speakers from around the world. Exciting times for kidney care! 🩺#PeritonealDialysis
November 5, 2025 at 11:08 PM
The first-ever Home Dialysis Early Program Course is happening today at #KidneyWk2025! 🌟
Thanks to ISPD collaboration with ASN, over 100 attendees can explore the latest trends in home dialysis with great speakers from around the world. Exciting times for kidney care! 🩺#PeritonealDialysis
Thanks to ISPD collaboration with ASN, over 100 attendees can explore the latest trends in home dialysis with great speakers from around the world. Exciting times for kidney care! 🩺#PeritonealDialysis
Reposted
Ahead of #KidneyWk25, we are recruiting a hypertension fellow to the Stanford Hypertension Center for July 2026. Please come find me at ASN.
med.stanford.edu/nephrology/e...
med.stanford.edu/nephrology/e...
Hypertension Fellowship
med.stanford.edu
November 5, 2025 at 7:57 AM
Ahead of #KidneyWk25, we are recruiting a hypertension fellow to the Stanford Hypertension Center for July 2026. Please come find me at ASN.
med.stanford.edu/nephrology/e...
med.stanford.edu/nephrology/e...
Reposted
Dual-Antigen Membranous Nephropathy
doi.org/10.1016/j.kint.2025.10.006
#NephSky #MedSky #membranousnephropathy @mayoclinicpath.bsky.social @arkanalabs.bsky.social @lynncornell.bsky.social @aaronstorey.bsky.social
doi.org/10.1016/j.kint.2025.10.006
#NephSky #MedSky #membranousnephropathy @mayoclinicpath.bsky.social @arkanalabs.bsky.social @lynncornell.bsky.social @aaronstorey.bsky.social
November 4, 2025 at 10:16 PM
Reposted
Moving beyond N of 1 case reports!
The first clinical trial of 🐷 kidneys begins
N = 6, poss or expansion to 50
United Therapeutics (NYU, UAB have used this model)
ca.finance.yahoo.com/news/first-c...
The first clinical trial of 🐷 kidneys begins
N = 6, poss or expansion to 50
United Therapeutics (NYU, UAB have used this model)
ca.finance.yahoo.com/news/first-c...
First clinical trial of pig kidney transplants gets underway
WASHINGTON (AP) — The first clinical trial is getting underway to see if transplanting pig kidneys into people might really save lives.
ca.finance.yahoo.com
November 4, 2025 at 1:15 AM
Moving beyond N of 1 case reports!
The first clinical trial of 🐷 kidneys begins
N = 6, poss or expansion to 50
United Therapeutics (NYU, UAB have used this model)
ca.finance.yahoo.com/news/first-c...
The first clinical trial of 🐷 kidneys begins
N = 6, poss or expansion to 50
United Therapeutics (NYU, UAB have used this model)
ca.finance.yahoo.com/news/first-c...
Reposted
Patient on Automated PD presents with hypotension, abdominal pain , fever for 2 days. Symptoms developed after colonoscopy with polypectomy.
October 31, 2025 at 3:05 PM
Patient on Automated PD presents with hypotension, abdominal pain , fever for 2 days. Symptoms developed after colonoscopy with polypectomy.
Reposted
If you get a clearly pathogenic COL4A5 variant you might be able to stop after genetic testing, but a single COL4A3/4 variant doesn’t tell you what’s going on in the kidney. Still need biopsies. #NephJC
October 29, 2025 at 1:49 AM
If you get a clearly pathogenic COL4A5 variant you might be able to stop after genetic testing, but a single COL4A3/4 variant doesn’t tell you what’s going on in the kidney. Still need biopsies. #NephJC
Reposted
Big holes:
Precedence of therapies
Options when one therapy runs out (e.g. Nefecon)
Lack of availability + cost of novel therapies
Lack of trials for 2+ concurrent therapies
Lack of apples-to-apples comparisons of therapies
And I love the idea of rolling guidance updates.
#NephJC
Precedence of therapies
Options when one therapy runs out (e.g. Nefecon)
Lack of availability + cost of novel therapies
Lack of trials for 2+ concurrent therapies
Lack of apples-to-apples comparisons of therapies
And I love the idea of rolling guidance updates.
#NephJC
October 29, 2025 at 1:57 AM
Big holes:
Precedence of therapies
Options when one therapy runs out (e.g. Nefecon)
Lack of availability + cost of novel therapies
Lack of trials for 2+ concurrent therapies
Lack of apples-to-apples comparisons of therapies
And I love the idea of rolling guidance updates.
#NephJC
Precedence of therapies
Options when one therapy runs out (e.g. Nefecon)
Lack of availability + cost of novel therapies
Lack of trials for 2+ concurrent therapies
Lack of apples-to-apples comparisons of therapies
And I love the idea of rolling guidance updates.
#NephJC
Reposted
What is the global incidence of IgA nephropathy?
Incidence is varied in different countries depending on urinary screening programs and timing of nephrology referral. There aren’t any validated serum markers and IgAN diagnosis is based exclusively on renal biopsy findings. #NephJC
Incidence is varied in different countries depending on urinary screening programs and timing of nephrology referral. There aren’t any validated serum markers and IgAN diagnosis is based exclusively on renal biopsy findings. #NephJC
October 29, 2025 at 1:08 AM
What is the global incidence of IgA nephropathy?
Incidence is varied in different countries depending on urinary screening programs and timing of nephrology referral. There aren’t any validated serum markers and IgAN diagnosis is based exclusively on renal biopsy findings. #NephJC
Incidence is varied in different countries depending on urinary screening programs and timing of nephrology referral. There aren’t any validated serum markers and IgAN diagnosis is based exclusively on renal biopsy findings. #NephJC
Does China have universal urinary screening in pediatrics?
I have quite a few folks who were diagnosed with IgA Nephropathy early in China before moving to the Bay Area for tech jobs
#NephJC
I have quite a few folks who were diagnosed with IgA Nephropathy early in China before moving to the Bay Area for tech jobs
#NephJC
Diagnosis: 🩺
Occurs in the 3rd- 4th decades of life, often after CKD has already set in.
🚨Highlighting the importance of urinary screening programs; measurement of UACR/UPCR.
Countries like Taiwan,Singapore,Australia had earlier diagnosis because of urinary screening programs. #NephJC
Occurs in the 3rd- 4th decades of life, often after CKD has already set in.
🚨Highlighting the importance of urinary screening programs; measurement of UACR/UPCR.
Countries like Taiwan,Singapore,Australia had earlier diagnosis because of urinary screening programs. #NephJC
October 29, 2025 at 1:15 AM
Does China have universal urinary screening in pediatrics?
I have quite a few folks who were diagnosed with IgA Nephropathy early in China before moving to the Bay Area for tech jobs
#NephJC
I have quite a few folks who were diagnosed with IgA Nephropathy early in China before moving to the Bay Area for tech jobs
#NephJC
Reposted
Brush up on the @kdigo.org IgAN guidelines with this #NephGR from Prof IgA Jon Barratt
youtu.be/OChs5BcTEGE?...
#NephJC in a couple of hours tonight!
youtu.be/OChs5BcTEGE?...
#NephJC in a couple of hours tonight!
Updates to the KDIGO Guidelines for the treatment of IgA nephropathy, with Prof Jonathan Barratt
YouTube video by Ottawa Nephrology
youtu.be
October 28, 2025 at 10:33 PM
Brush up on the @kdigo.org IgAN guidelines with this #NephGR from Prof IgA Jon Barratt
youtu.be/OChs5BcTEGE?...
#NephJC in a couple of hours tonight!
youtu.be/OChs5BcTEGE?...
#NephJC in a couple of hours tonight!
Reposted
Check out the insightful summary by
Bogdan Agavriloaei @thekidneywhisperer.bsky.social and
Janany Sabescumar @glomerican.bsky.social
www.nephjc.com/news/...
#NephJC
Bogdan Agavriloaei @thekidneywhisperer.bsky.social and
Janany Sabescumar @glomerican.bsky.social
www.nephjc.com/news/...
#NephJC
2025 IgAN KDIGO guidelines: fresh out of press, already aging gracefully — NephJC
This week, we will discuss the 2025 KDIGO IgAN guidelines. which the shift
from supportive care to structured, evidence-based therapy
www.nephjc.com
October 29, 2025 at 1:03 AM
Check out the insightful summary by
Bogdan Agavriloaei @thekidneywhisperer.bsky.social and
Janany Sabescumar @glomerican.bsky.social
www.nephjc.com/news/...
#NephJC
Bogdan Agavriloaei @thekidneywhisperer.bsky.social and
Janany Sabescumar @glomerican.bsky.social
www.nephjc.com/news/...
#NephJC
October 29, 2025 at 1:07 AM
Reposted
🎨Beautiful visual abstract by Dr Natalia Nombera @roxnonna23.bsky.social #NephJC
www.nephjc.com/news/...
www.nephjc.com/news/...
October 29, 2025 at 1:04 AM
🎨Beautiful visual abstract by Dr Natalia Nombera @roxnonna23.bsky.social #NephJC
www.nephjc.com/news/...
www.nephjc.com/news/...
Reposted
The 2025 @kdigo.org IgAN guideline quietly redraws the map: new drugs, new thresholds, and a sense that the era of “supportive care only” is finally over #Nephsky #Medsky
✍️Summary by @thekidneywhisperer.bsky.social and
@glomerican.bsky.social
www.nephjc.com/news/igan-kd...
✍️Summary by @thekidneywhisperer.bsky.social and
@glomerican.bsky.social
www.nephjc.com/news/igan-kd...
2025 IgAN KDIGO guidelines: fresh out of press, already aging gracefully — NephJC
This week, we will discuss the 2025 KDIGO IgAN guidelines. which the shift from supportive care to structured, evidence-based therapy
www.nephjc.com
October 28, 2025 at 2:06 AM
The 2025 @kdigo.org IgAN guideline quietly redraws the map: new drugs, new thresholds, and a sense that the era of “supportive care only” is finally over #Nephsky #Medsky
✍️Summary by @thekidneywhisperer.bsky.social and
@glomerican.bsky.social
www.nephjc.com/news/igan-kd...
✍️Summary by @thekidneywhisperer.bsky.social and
@glomerican.bsky.social
www.nephjc.com/news/igan-kd...
Reposted
There is an ongoing danish study called APPLE TREE randomizing patients who are being perscribed SGLT2i to either empa, dapa or cana. Maybe we’ll ger the answer here: lundbeckfonden.com/en/the-apple...
The APPLE TREE study
Daniel Christensen, Department of Cardiology, Herlev and Gentofte Hospital, has been awarded an Early-career clinician scientist research grant worth DKK 916.199.
lundbeckfonden.com
October 21, 2025 at 6:34 PM
There is an ongoing danish study called APPLE TREE randomizing patients who are being perscribed SGLT2i to either empa, dapa or cana. Maybe we’ll ger the answer here: lundbeckfonden.com/en/the-apple...